

## Missed or delayed doses of extended-release tacrolimus in transplantation: impact on exposure and mitigation strategies

Arraki Zava S<sup>1</sup>, Sayadi H<sup>1</sup>, Fromage Y<sup>1,2</sup>, Maizaud F<sup>1</sup>, Marquet P<sup>1-3</sup>, Labriffe M<sup>1-3</sup>, Woillard JB<sup>1-3</sup>, Monchaud C<sup>1-3</sup>

<sup>1</sup>Department of Pharmacology, Toxicology and Pharmacovigilance, CHU Limoges, Limoges, France; <sup>2</sup>Pharmacology & Transplantation, INSERM U1248, Limoges University, Limoges, France; <sup>3</sup>Fédération Hospitalo-Universitaire Survival Optimization in Organ Transplantation (FHU SUPPORT), Limoges, France.

**Background.** In a lifelong treatment such as with immunosuppressants, there is a high risk of missing a dose, inducing underexposure and loss of efficacy. Strategies limiting the impact of missed doses of immediate-release tacrolimus have already been proposed. Our objective was to find such strategies for prolonged-release tacrolimus (PR-tacrolimus).

**Methods.** Three population pharmacokinetic models developed in stable kidney and liver transplant recipients on PR-tacrolimus (Moes et al. 2015, Benkali et al. 2010, Martial et al. 2021) were implemented in R software version 4.3.2. Tacrolimus pharmacokinetic profiles of 1000 patients at steady state (SS) were simulated, with doses targeting trough concentrations ( $C_0$ ) of 5 or 7.5  $\mu\text{g/L}$ . Various scenarios were considered, from a 3-hours delayed dose to a completely missed dose. The effect of a missed dose on tacrolimus exposure was evaluated on the following area under the curve over 24 hours ( $\text{AUC}_{0-24\text{h}}$ ) and on the  $C_0$ . The relative difference (RD) between SS and up to five days after the missed dose was calculated for  $C_0$  and  $\text{AUC}_{0-24\text{h}}$ . Different dose adjustments scenarios allowing the restoration of exposure as fast as possible were tested.

**Results.** A 3-hour delayed dose induced a variation of +1 to +14% on the following  $C_0$  and -1 to -4% on the following  $\text{AUC}_{0-24\text{h}}$ , depending on the models. A missed dose resulted in a variation of -12 to -65% on the following  $C_0$  and -24 to -67% on the following  $\text{AUC}_{0-24\text{h}}$ , while five days were necessary for both exposure indices to reach their initial SS values. The best strategies restoring appropriate exposure depended on the dosing interval and were the following: immediate intake of the full dose for a delay of less than 12 hours; intake of 150% of the original dose at the time of the next scheduled dose, for a 12 to 24-hour delay.

**Conclusions.** Pharmacokinetic simulations provided valuable data on how to handle delayed or missed doses in kidney and liver transplant recipients receiving PR-tacrolimus. These recommendations should be applied in order to minimize the risk of graft rejection and adverse effects.

**Keywords.** Prolonged-release tacrolimus, population pharmacokinetics, delayed dose, missed dose, renal transplantation, liver transplantation.